Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

New England Journal of Medicine

Volumn 370, Issue 20, 2014, Pages 1889-1898

  Afdhal, Nezam ^a   Zeuzem, Stefan ^b   Kwo, Paul ^d   Chojkier, Mario ^e   Gitlin, Norman ^g   Puoti, Massimo ^h   Romero Gomez, Manuel ^j   Zarski, Jean Pierre ^l   Agarwal, Kosh ⁿ   Buggisch, Peter ^c   Foster, Graham R ^o   Bräu, Norbert ^p   Buti, Maria ^k   Jacobson, Ira M ^q   Subramanian, G Mani ^f   Ding, Xiao ^f   Mo, Hongmei ^f   Yang, Jenny C ^f   Pang, Phillip S ^f   Symonds, William T ^f   McHutchison, John G ^f   Muir, Andrew J ^r   Mangia, Alessandra ⁱ   Marcellin, Patrick ^m   more..

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UCSD MEDICAL CENTER   (United States)

^f GILEAD SCIENCES   (United States)

^g Atlanta Gastroenterology Associates   (United States)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁱ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^j HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m BEAUJON HOSPITAL   (France)

ⁿ KING S COLLEGE HOSPITAL   (United Kingdom)

^o QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^p VETERANS AFFAIRS MEDICAL CENTER   (United States)

^q WEILL CORNELL MEDICAL COLLEGE   (United States)

^r DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CELLULITIS; CONTROLLED STUDY; COUGHING; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROENTERITIS; HAND FRACTURE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS RESISTANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; URIDINE MONOPHOSPHATE; VIRAL LOAD; YOUNG ADULT;

EID: 84900339263     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1402454     Document Type: Article

References (21)

1. Sovaldi (sofosbuvir) tablets: US prescribing information. Foster City, CA: Gilead Sciences, December 2013 (http://www.gilead.com/~/media/Files/pdfs/ medicines/liver-disease/sovaldi/sovaldi-pi.pdf).
2. Olysio (simeprevir) capsules: US prescribing information. Titusville, NJ: Janssen Therapeutics, November 2013 (http://www.olysio.com/shared/product/ olysio/prescribing-information.pdf).
3. Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 2013 July 18 (Epub ahead of print).
4. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310:804-11. [Erratum, JAMA 2013;310:1987.]
5. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
6. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
7. Rebetol (ribavirin) capsules: US prescribing information. Whitehouse Station, NJ: Merck, 2003 (https://www.merck.com/product/usa/pi-circulars/r/ rebetol/rebetol-pi.pdf).
8. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C (http://www.hcvguidelines.org).
9. Lawitz EJ, Gruener D, Hill JM, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012;57:24-31.
10. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C: an open-label, randomized, phase 2 trial (LONESTAR). Lancet 2014;383:515-23. [Erratum, Lancet 2014;383:870.]
11. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B nonnucleoside inhibitor GS-9669 against hepatitis C genotype 1 infection. Gastroenterology 2013; 146:736-43.
12. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
14. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
15. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44.
16. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
17. Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2014;146:442-52.
18. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
19. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
20. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013;59:434-41.
21. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368: 1867-77.